786 844
Financial disclosures:
Pernilla Wikstro¨m certifies that all conflicts of
interest, including specific financial interests and relationships and
affiliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/affiliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents filed, received, or pending), are the following: None.
Funding/Support and role of the sponsor:
This study was supported by
grants from Swedish Research Council (K2013-64X-20407-04-3), the
Swedish Cancer Society (CAN 2013/845 and CAN 2013/1324), The
Swedish Foundation for Strategic Research (RB13-0119), Cancer
Research Foundation in Northern Sweden, Umea˚ University, the county
of Va¨sterbotten, and the Erling-Persson Family Foundation. The sponsors
played no direct role in the study.
Acknowledgments:
The authors are grateful to Pernilla Andersson and
Susanne Gidlund for excellent technical assistance.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2016.07.033 .References
[1]
Nelson PS. Molecular states underlying androgen receptor activa- tion: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol 2012;30:644–6.[2]
Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel che- motherapy. Ther Adv Urol 2014;6:3–14.
[3]
Ho¨rnberg E, Ylitalo EB, Crnalic S, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 2011;6:e19059.
[4]
Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028–38.[5]
Jernberg E, Thysell E, Bovinder Ylitalo E, et al. Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants. PLoS One 2013;8:e77407.
[6]
Crnalic S, Ho¨rnberg E, Wikstro¨m P, et al. Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients. Endocr Relat Cancer 2010;17:885–95.[7]
Hammarsten P, Karalija A, Josefsson A, et al. Low levels of phos- phorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res 2010;16:1245–55.[8]
Eriksson L, Antti H, Gottfries J, et al. Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem 2004;380:419–29.[9]
Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunother- apy. Urology 1995;46:681–6.[10]
Seliger B, Stoehr R, Handke D, et al. Association of HLA class I antigen abnormalities with disease progression and early recur- rence in prostate cancer. Cancer Immunol Immunother 2010;59: 529–40.[11]
Kitamura H, Torigoe T, Asanuma H, Honma I, Sato N, Tsukamoto T. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J Urol 2007;178:692–6.
[12]
Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, et al. Suppres- sion of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012;22:373–88.[13]
Thysell E, Surowiec I, Ho¨rnberg E, et al. Metabolomic characteriza- tion of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One 2010;5:e14175.
[14]
Iglesias-Gato D, Wikstro¨m P, Tyanova S, et al. The proteome of primary prostate cancer. Eur Urol 2016;69:942–52.
[15]
Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immu- notherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015;14:561–84.
[16]
Marchesi M, Andersson E, Villabona L, et al. HLA-dependent tumour development: a role for tumour associate macrophages? J Transl Med 2013;11:247.
[17]
Strasner A, Karin M. Immune Infiltration and Prostate Cancer. Front Oncol 2015;5:128.
[18]
Davidsson S, Ohlson AL, Andersson SO, et al. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3 + regulatory T cells with respect to lethal prostate cancer. Mod Pathol 2013;26:448–55.
[19]
Flammiger A, Weisbach L, Huland H, et al. High tissue density of FOXP3 + T cells is associated with clinical outcome in prostate cancer. Eur J Cancer 2013;49:1273–9.
[20]
Lanciotti M, Masieri L, Raspollini MR, et al. The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. BioMed Res Int 2014;2014:486798.
[21]
Tidehag V, Hammarsten P, Egevad L, et al. High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome. Eur J Cancer 2014;50:1829–35.
[22]
Lundholm M, Ha¨gglo¨f C, Wikberg ML, et al. Secreted factors from colorectal and prostate cancer cells skew the immune response in opposite directions. Sci Rep 2015;5:15651.
[23]
Idorn M, Kollgaard T, Kongsted P, Sengelov L, Thor Straten P. Correlation between frequencies of blood monocytic myeloid-de- rived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother 2014;63:1177–87.
[24]
Wang L, Gong Y, Chippada-Venkata U, et al. A robust blood gene expression-based prognostic model for castration-resistant pros- tate cancer. BMC Med 2015;13:201.
[25]
Saad F, Miller K. Current and emerging immunotherapies for cas- tration-resistant prostate cancer. Urology 2015;85:976–86.[26]
Pomerantz MM, Li F, Takeda DY, et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumori- genesis. Nat Genet 2015;47:1346–51.
[27]
Cheng XH, Black M, Ustiyan V, et al. SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene. PLoS Genet 2014;10:e1004656.
[28]
Kim IJ, Kang TW, Jeong T, Kim YR, Jung C. HOXB13 regulates the prostate-derived Ets factor: implications for prostate cancer cell invasion. Int J Oncol 2014;45:869–76.
[29]
Mlecnik B, Bindea G, Kirilovsky A, et al. The tumor microenviron- ment and immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med 2016;8, 327ra26.
[30]
Bukur J, Jasinski S, Seliger B. The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol 2012;22: 350–8.[31]
Chang CC, Pirozzi G, Wen SH, et al. Multiple structural and epige- netic defects in the human leukocyte antigen class I antigen pre- sentation pathway in a recurrent metastatic melanoma following immunotherapy. J Biol Chem 2015;290:26562–75.
[32]
Fonsatti E, Nicolay HJ, Sigalotti L, et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2 0 -E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 7 7 6 – 7 8 7
786